Department of Psychiatry, Jikei University School of Medicine, Tokyo, Japan.
Int Psychogeriatr. 2013 Jul;25(7):1199-201. doi: 10.1017/S1041610212002037. Epub 2012 Nov 30.
A 48-year-old woman with Parkinson disease (PD) suffered from auditory hallucinations (AH). We had treated her with a reduction in antiparkinsonian agents and the use of atypical antipsychotic agents. However, her symptoms did not improve, and her extrapyramidal symptoms (EPS) worsened. To lessen her depressive symptoms, treatment with a new-generation antidepressant, mirtazapine (MRZ), was commenced. The patient's AH gradually decreased with no worsening of EPS, and the AH disappeared 4 weeks after the commencement of treatment with MRZ. The present case suggests the effectiveness of MRZ for the treatment of refractory AHs in patients with PD.
一位 48 岁的帕金森病(PD)女性患者出现幻听(AH)。我们已通过减少抗帕金森病药物和使用非典型抗精神病药物对其进行了治疗。但是,她的症状并未改善,且其锥体外系症状(EPS)恶化。为减轻其抑郁症状,开始使用新一代抗抑郁药米氮平(MRZ)进行治疗。随着 EPS 无恶化,患者的 AH 逐渐减少,并且在开始使用 MRZ 治疗 4 周后,AH 消失。本病例提示 MRZ 对治疗 PD 患者的难治性 AH 可能有效。